Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Received NYSE AMEX Notice of Compliance ROCKVILLE, Md., Feb. 18 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE AMEX: CUR) announced today that it has raised a total of $5,228,000 since the...
ROCKVILLE, Md., Jan. 21 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that the first ALS patient was treated with its spinal cord stem cells yesterday at the Emory ALS...
ROCKVILLE, Md., Dec. 18 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Amex: CUR) today announced that its Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease...
ROCKVILLE, Md., Nov. 17 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Amex: CUR) today provided a financial and business update for the third quarter ended September 30, 2009. (Logo:...
ROCKVILLE, Md., Sept. 21 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug...
NEW YORK, April 6 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc. (NYSE Amex: CUR). The...
Make Synaptic Contact with Host Motor Neurons ROCKVILLE, Md., March 9 /PRNewswire-FirstCall/ -- Transplanted human neural stem cells (hNSCs) developed by Neuralstem, Inc. (NYSE Alternext US:...
ROCKVILLE, Md., Feb. 20 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Alternext US: CUR) announced today its spinal cord stem cell trial to treat ALS is on clinical hold and that the Federal...
ROCKVILLE, Md., Feb. 12 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Alternext US: CUR) announced today that James Sasser, former Senator (D-Tennessee) and former Ambassador to the People's...
ROCKVILLE, Md., Feb. 2 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Alternext US: CUR) announced today that Richard Garr, CEO and President, will present at the 11th Annual BIO CEO...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 1.17 | 1.17 | 1.17 | 0 | 0 | DE |
| 4 | 0 | 0 | 1.17 | 1.17 | 1.17 | 0 | 0 | DE |
| 12 | 0 | 0 | 1.17 | 1.17 | 1.17 | 0 | 0 | DE |
| 26 | 0 | 0 | 1.17 | 1.17 | 1.17 | 0 | 0 | DE |
| 52 | 0 | 0 | 1.17 | 1.17 | 1.17 | 0 | 0 | DE |
| 156 | 0 | 0 | 1.17 | 1.17 | 1.17 | 0 | 0 | DE |
| 260 | 0 | 0 | 1.17 | 1.17 | 1.17 | 0 | 0 | DE |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
